Although patients will notice little difference between 2D and 3D mammograms, the 3D technology gives the radiologist a clearer view through the overlapping structures of breast tissue.
Reading a breast tomosynthesis exam is like flipping through the pages of a book to view one page at a time instead of seeing the whole breast reduced to a single frame, as is the case with conventional 2D mammography.
Yaffe, Ph D, the Tory Family Chair of Cancer Research at Sunnybrook Health Sciences Centre and the lead researcher for the Canadian arm of the trial.
“TMIST will provide solid evidence as to the impact that we can expect in reducing the burden of breast cancer on women and their loved ones.” More than 3000 Canadian women participated in a lead-in study led by Dr.
Pisano, MD, professor in residence at Beth Israel Deaconess Medical Center and Harvard Medical School, and chief science officer at the Center for Research and Innovation at the American College of Radiology.
“This trial is not only about which technology works best, it is about how we can help individual women get what they need to avoid death from breast cancer.” “We should always base decisions about adopting new medical technologies on scientific evidence,” said Martin J.
This undesired adverse impact can be avoided by using synthesised 2D images reconstructed from the DBT data (s2D).
We designed a diagnostic superiority trial on a high level of evidence with the aim of providing a comparison of screening efficacy parameters resulting from DBT s2D versus the current screening standard 2D full-field digital mammography (FFDM) in a multicentre and multivendor setting on the basis of the quality-controlled, population-based, biennial mammography screening programme in Germany.
3D mammography or digital breast tomosynthesis is a new imaging technology that can identify small cancers not visible on traditional 2D mammography.
If cancers are found when they are small, treatment options are generally less traumatic and the chance for a cure is greater.